(616: Kb)

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort (616 KB)

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. Toxicities and outcomes of 616 ibrutinib-treated patients in

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). available through PubMed Central (PMC)